Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

U.S.PATENTS

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10518110		
Filing Date		2005-10-26		
First Named Inventor	Lynne	Canne Bannen		
Art Unit		1624		
Examiner Name	Ebenezer O. Sackey			
Attorney Docket Number		02-280-F		

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date		Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1									
If you wisl	If you wish to add additional U.S. Patent citation information please click the Add button.									
	U.S.PATENT APPLICATION PUBLICATIONS									
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date		Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1									
If you wisl	h to ac	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ade	butto	on.	
				FOREIG	SN PAT	ENT DOCUM	ENTS			
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j		Kind Code4	Publication Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	<b>T</b> 5
	1	97/20824	wo		A1	1997-06-12	Agourdon Pharma			
	2	98/32748	wo		A1	1998-07-30	Hoffmann La Roche et al.			
	3	1 016 245	GB		A1	1966-01-05	ICI Ltd.			

## INFORMATION DISCLOSURE

( Not for submission under 37 CFR 1.99)

Application Number		10518110			
Filing Date		2005-10-26			
First Named Inventor	Lynne	Lynne Canne Bannen			
Art Unit		1624			
Examiner Name	Ebenezer O. Sackey				
Attornov Dooket Number		02.280.E			

						4.0				
	4	98/43963	wo	A1	1998-10-08	Agourdon Pharma				
	5	01/55112	wo	A1	2001-08-02	American Cyanamid Co.				
	6	03/051825	wo	A1	2003-06-26	Exelixis, Inc.				
If you wis	h to a	dd additional For	eign Patent Docu	ment citatio	n information p	please click the Add button				
			NON-P	ATENT LIT	TERATURE DO	CUMENTS				
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								
	1	FEIT et al., "Structure-activity studies on sulfamyl diuretics", Journal of Medicinal Chemistry, 15(4), 1972, 437-440.								
	2	SHAHRIPOUR, A. B. et al., "Structure-based design of caspase - 1 inhibitor containing a diphenyl ether sulfonamide", Biorganic & Medicinal Chemistry Letters, 11(20), 2001, 2779-2782.								
	3	NEALE, A. J. et al., "Internuclear cyclizations of aromatic sulfonyl chlorides. Tribenz [b,d,f] oxepin and tribenzo [b,d,f] thiepin", Tetrahedron, 21(6), 1299-313.								
If you wis	h to a	dd additional non	-patent literature	document o	citation informa	tion please click the Add buttor	1			
				EXAMIN	ER SIGNATUI	RE				
Evaminer	Sign	oture				Date Considered				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USPTO Patent Documents at <a href="https://www.USPTO.GOV">www.USPTO.GOV</a> or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.